June 25, 2019 | City of Hope
City of Hope has accelerated its plans for a $1 billion comprehensive cancer campus in Orange County, bringing highly specialized cancer care, clinical trials, precision medicine and early detection to the nation’s sixth most populous county.
Super cells could help doctors detect cancer seven years sooner
July 18, 2019 | Maxine Nunes
Tiny molecular "packages" can be harnessed for diagnosis and treatment of cancer, diabetes and other diseases, City of Hope researchers are discovering.
TGen IDs gene associated with most common liver cancer
April 19, 2019 | City of Hope
AKR1B10 could help provide early detection of hepatocellular carcinoma, and play a role in monitoring and treating this growing cause of cancer death.
Study explores why glioblastoma affects sexes differently
February 25, 2019 | City of Hope
A nationwide team of researchers that includes City of Hope’s Translational Genomics Research Institute (TGen) has identified molecular differences that explain why men die of glioblastoma, a type of brain cancer, at nearly twice the rate of women.
For this diabetes researcher, the mission is personal
December 5, 2018 | City of Hope
Sampath Rangasamy, Ph.D., a researcher at City of Hope affiliate TGen, has spent his whole life researching type 1 diabetes, a personal battle since he himself suffers from the disease.
Big data for better results: the power and the promise of precision medicine
September 26, 2018 | Sam Lazaryev
Jeff Trent, Ph.D., TGen president and research director, discusses the promise of precision medicine and his company’s exciting initiative with City of Hope.
TGen tackles diabetic blindness with new collaboration
September 25, 2018 | City of Hope
City of Hope affiliate TGen has been awarded a $2.8 million grant in an effort to discover new treatments for diabetic retinopathy.
Researcher's Ovarian Cancer Discovery Takes on Special Meaning
June 27, 2018 | City of Hope
The results of a study published earlier this year by TGen researchers (City of Hope affiliate) in the journal Clinical Cancer Research suggest an existing leukemia drug, ponatinib, shows promise against SCCOHT.